Log in to search using one of your social media accounts:

 

Pixium Vision touts 1st use of Prima bionic vision system
Pixium Vision (EPA:PIX) yesterday announced the first successful trial implantation and activation of its Prima next-generation miniaturized wireless photovoltaic sub-retinal implant, and that the system successfully produced visual perception. With the implantation complete, the patient will begin the re-education phase of the study which includes a six-month and 36-month follow-up, the Paris-based company said. “This first successful activation is a major milestone, validating Prima’s concept in patients with advanced dry AMD. The close collaboration between our team at Stanford University and Pixium Vis...
Source: Mass Device - January 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news

Innovation Lab eyes local professor as first incubator tenant
The University of Tennessee Health Science Center (UTHSC) has selected a local ophthalmology professor as the first user of its new Innovation Lab. Monica M. Jablonski, who works in UTHSC's College of Medicine, is developing a topical mixture that works better than standard eye drops and is working to improve treatments for conditions such as glaucoma and age-related macular degeneration. Jablonski and her company, OculoTherapy LLC, will ha ve access to the 420-square-foot space within the Memphis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 24, 2018 Category: Pharmaceuticals Authors: Elle Perry Source Type: news

Innovation Lab eyes local professor as first incubator tenant
The University of Tennessee Health Science Center (UTHSC) has selected a local ophthalmology professor as the first user of its new Innovation Lab. Monica M. Jablonski, who works in UTHSC's College of Medicine, is developing a topical mixture that works better than standard eye drops and is working to improve treatments for conditions such as glaucoma and age-related macular degeneration. Jablonski and her company, OculoTherapy LLC, will ha ve access to the 420-square-foot space within the Memphis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 24, 2018 Category: Biotechnology Authors: Elle Perry Source Type: news

Is Age-Related Macular Degeneration Declining? Is Age-Related Macular Degeneration Declining?
An aging population should mean an uptick in age-related macular degeneration cases, but recent data suggest that is not what's happening.Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - January 18, 2018 Category: Opthalmology Tags: Ophthalmology Commentary Source Type: news

Vitamins for Age-Related Macular Degeneration Vitamins for Age-Related Macular Degeneration
A look at the evidence supporting vitamin therapy for the most common cause of vision loss in US adults: age-related macular degeneration.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Ophthalmology Commentary Source Type: news

Ohr Pharmaceutical shares plummet after eye drug fails in wet-AMD trial
Shares in Ohr Pharmaceutical (NSDQ:OHRP) dropped -83% to trade at 35¢ apiece this morning after the company revealed that its topical therapy did not meet the primary endpoint of a trial evaluating its efficacy as a treatment for wet age-related macular degeneration. The company’s Mako study randomized patients 1:1 to receive either Ohr’s topical, twice-daily squalamine therapy in combination with monthly Lucentis injections or a placebo combined with Lucentis. Get the full story at our sister site, Drug Delivery Business News. The post Ohr Pharmaceutical shares plummet after eye drug fails in we...
Source: Mass Device - January 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat ohrpharmaceutical Source Type: news

Pixium Vision wins FDA nod for Prima sub-retinal implant study
Pixium Vision (EPA:PIX) said today it won FDA approval to launch a clinical feasibility trial of its Prima next-gen miniaturized wireless photovoltaic sub-retinal implant designed to treat patients with atrophic dry age-related macular degeneration. The trial of the device, which is slated to be conducted at the University of Pittsburgh Medical Center, aims ot recruit 5 patients with vision loss due to atrophic dry age-related macular degeneration, the Paris-based company said. The study’s primary endpoint will be the restoration of visual perception and safety at 12-months, with a longer-term follow up at ...
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Pixium Vision Source Type: news

Mylan, Momenta take aim at Regeneron ’ s Eylea with biosimilar
Momenta Pharmaceuticals (NSDQ:MNTA) and Mylan (NSDQ:MYL) announced yesterday that they plan to launch a pivotal trial in the first half of 2018 for a proposed biosimilar to Regeneron‘s (NSDQ:REGN) blockbuster drug, Eylea. Eylea, a VEGF-inhibitor designed to treat wet age-related macular degeneration and diabetic macular edema, has little competition on today’s market. The drug brought in more than $5 billion for Regeneron in 2016. Get the full story at our sister site, Drug Delivery Business News. The post Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar appeared first on M...
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat momentapharmaceuticals Mylan Regeneron Source Type: news

A New Form of This Miracle Nutrient Is 8 Times More Powerful …
CoQ10 has made the mainstream. You can find it everywhere. But the type of CoQ10 I want to tell you about has been completely ignored. That’s too bad, because this new form is 8 times better at getting into your blood and staying there. And that’s where it has its miracle-like anti-aging effects. This new form of CoQ10 may give you the opportunity to live disease-free for the rest of your life. Today, I’ll show you how this new “reduced” form of CoQ10 gives you greater power to prevent and reverse disease. You’ll also discover that it ramps up your energy levels and slows your aging proc...
Source: Al Sears, MD Natural Remedies - January 3, 2018 Category: Complementary Medicine Authors: Francisco Cabrera Tags: Nutrition antioxidants CoQ10 ubiquinol Source Type: news

NIH discovery brings stem cell therapy for eye disease closer to the clinic
(NIH/National Eye Institute) Scientists at the National Eye Institute report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE) -- a layer of cells in the back of the eye -- are essential for the survival of the retina's light-sensing photoreceptors. The discovery has advanced efforts to make stem cell-derived RPE for transplantation into patients with geographic atrophy, otherwise known as dry age-related macular degeneration (AMD), a leading cause of blindness in the US. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 2, 2018 Category: Biology Source Type: news

A drug to treat retinal diseases with drops instead of injections
(FECYT - Spanish Foundation for Science and Technology) The Spanish firm Sylentis has developed a compound to treat diseases of the retina, such as age-related macular degeneration and diabetic retinopathy, which will be administered by ophthalmic drops instead of intraocular injections. The drug, which has been tested in animals, is a small interfering RNA capable of penetrating the cells of the retina and blocking the formation of new blood vessels. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 12, 2017 Category: International Medicine & Public Health Source Type: news

At-home vision monitoring app may improve patient care
(American Academy of Ophthalmology) Patients with age-related macular degeneration or diabetic retinopathy who used a mobile application to test their vision at home got comparable results to in-office vision testing, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2017 Category: International Medicine & Public Health Source Type: news

LumiThera touts interim data from pilot study of LT-300 AMD treatment
LumiThera today announced topline interim results from the Lightsite 1 trial of its LT-300 photobiomodulation device designed to treat dry age-related macular degeneration, touting statistically significant vision benefits maintained to 3 months. Data came from the 30-patient pilot study of the device, funded by a Small Business Innovation Research grant from the National Institute of Health and National Eye Institute. The trial is slated to follow patients undergoing photobiomodulation therapies for up to 1 year. “We have examined the interim data from the Lightsite I study for up to the first 3 months followin...
Source: Mass Device - November 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic LumiThera Source Type: news

Stem Cell Therapy Among Hot Topics at AAO 2017 Stem Cell Therapy Among Hot Topics at AAO 2017
A potential treatment for two eye conditions that currently have none -- inherited retinal disease and dry age-related macular degeneration -- will be among the most anticipated research presented at AAO 2017.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Blindness treatment: Eat THIS £1 food to cut risk of vision loss
VISION loss affects almost two million people in the UK. The leading cause of vision loss is age-related macular degeneration , which currently affects about 600,000 people in the country. (Source: Daily Express - Health)
Source: Daily Express - Health - November 2, 2017 Category: Consumer Health News Source Type: news

Drug giants' legal threat to the NHS for using cheap drugs
Novartis and Bayer made the threat against 12 health boards in Cumbria and North-East England which have advised doctors to use a different treatment for age-related macular degeneration. (Source: the Mail online | Health)
Source: the Mail online | Health - November 1, 2017 Category: Consumer Health News Source Type: news

LumiThera Closes Series B Round of Financing
SEATTLE, Oct. 31, 2017 -- (Healthcare Sales & Marketing Network) -- LumiThera Inc., a clinical stage private medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has comple... Devices, Ophthalmology, Venture Capital, Personnel LumiThera, photobiomodulation, Age-related Macular Degeneration, dry AMD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2017 Category: Pharmaceuticals Source Type: news

LumiThera raises $6m in Series B
LumiThera said today it raised $5.5 million in a Series B round of financing to support the development of its LT-300 device designed for treating dry age-related macular degeneration. Proceeds from the round will support pursuit of regulatory clearance for the LT-300 device outside the US, including CE Mark approval in the European Union and additional clinical and commercial activities, the Seattle-based company said. “We are pleased with the investor interest in the company and have oversubscribed the Series B round. This is an exciting time for the company and the infusion of new capital will allow us to exe...
Source: Mass Device - October 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News LumiThera Source Type: news

MassDevice.com +5 | The top 5 medtech stories for October 19, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. This surgical glue seals wounds in 60 seconds A potentially life-saving surgical glue that is highly elastic and adhesive can quickly seal wounds in seconds without the need for common staples or sutures. The surgical glue, cal...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Pixium Vision wins French approval for Prima sub-retinal implant study
Pixium Vision (EPA:PIX) said today it won approval from France’s regulatory agency to launch a feasibility clinical study of its next-gen Prima sub-retinal implant in patients with advanced dry age-related macular degeneration. The Prima system is a next-gen wireless implant with a micro photovoltaic chip designed to be implanted under the retina to convert pulsed near-infra-red invisible light received from external glasses with an integrated mini-camera into electrical signals transmitted to the brain through the optic nerve, the company said. The system is designed to treat retinal dystrophies with a foc...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news

Cell-Based Therapy for Dry AMD Promising in Early Trial Cell-Based Therapy for Dry AMD Promising in Early Trial
A cell-based therapy derived from umbilical cord tissue could someday treat geographic atrophy caused by age-related macular degeneration, early trials of this novel therapy suggest.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 15, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Can Assessment of Age-related Macular Degeneration Be Automated? Can Assessment of Age-related Macular Degeneration Be Automated?
Automated assessment of age-related macular degeneration (AMD) from fundus images could play a role in managing the disease, according to a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 9, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Key Micronutrients and Food Groups in Late-Stage AMD Key Micronutrients and Food Groups in Late-Stage AMD
How does nutritional intake differ between healthy patients and those with late-stage age-related macular degeneration?The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2017 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Blood metal ion levels can identify hip replacement patients at low risk of ARMD
(Wolters Kluwer Health) Patients with 'metal on metal' artificial hips are at risk of complications caused by adverse reactions to metal debris (ARMD). A study in the Sept. 20, 2017, issue of the Journal of Bone& Joint Surgery confirms that blood metal ion levels specific to the type of hip implant used can help predict patients who are at low risk of ARMD. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2017 Category: International Medicine & Public Health Source Type: news

AMD: Brolucizumab Noninferior to Aflibercept in Early Study AMD: Brolucizumab Noninferior to Aflibercept in Early Study
A small phase 2 study suggests that brolucizumab is as safe and effective as aflibercept for treating patients with age-related macular degeneration.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche today announced that the primary endpoint has not been met in Spectri, the first of two phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). (Source: Roche Media News)
Source: Roche Media News - September 8, 2017 Category: Pharmaceuticals Source Type: news

Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche today announced that the primary endpoint has not been met in Spectri, the first of two phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). (Source: Roche Investor Update)
Source: Roche Investor Update - September 8, 2017 Category: Pharmaceuticals Source Type: news

Fund cheap supplement for degenerative eye disease, NHS urged
Antioxidant and zinc combo effective for slowing wet age-related macular degeneration Related items fromOnMedica Dementia risk no higher in people with AMD Age-Related Macular Degeneration First patient receives new treatment for AMD (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 25, 2017 Category: UK Health Source Type: news

Zink May Help Against Vision Loss in Seniors
But no large studies prove the inexpensive pill slows age-related macular degeneration, eye expert says (Source: WebMD Health)
Source: WebMD Health - August 24, 2017 Category: Consumer Health News Source Type: news

Supplement May Help Against Vision-Robbing Disease in Seniors
But no large studies prove the inexpensive pill slows age-related macular degeneration, eye expert says Source: HealthDay Related MedlinePlus Pages: Complementary and Integrative Medicine, Macular Degeneration (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 24, 2017 Category: Consumer Health News Source Type: news

Supplement May Help Against Vision-Robbing Disease in Seniors
But no large studies prove the inexpensive pill slows age-related macular degeneration, eye expert says (Source: WebMD Health)
Source: WebMD Health - August 24, 2017 Category: Consumer Health News Source Type: news

Zinc May Help Against Vision Loss in Seniors
But no large studies prove the inexpensive pill slows age-related macular degeneration, eye expert says (Source: WebMD Health)
Source: WebMD Health - August 24, 2017 Category: Consumer Health News Source Type: news

New Anti-VEGF Drug Promising for Wet Macular Degeneration New Anti-VEGF Drug Promising for Wet Macular Degeneration
OPT-302, a new vascular endothelial growth factor (VEGF) inhibitor, appears to be safe and shows signs it could slow the progression of neovascular age-related macular degeneration.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Opthea touts data from wet-AMD trial
Opthea (ASX:OPT) touted additional data today from the Phase I/IIa trial of its wet age-related macular degeneration therapy, OPT-302. The 50-patient Phase I/IIa trial recruited participants who were either treatment-naive or previously treated with an intravitreal anti-VEGF therapy. Researchers evaluated OPT-302 as a monotherapy and in combination with Lucentis (ranibizumab). Get the full story at our sister site, Drug Delivery Business News. The post Opthea touts data from wet-AMD trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Opthea Source Type: news

Robot saved my sight by blasting my eye with radiotherapy
Michael Edwards (pictured), from Fawsley in Northamptonshire, was diagnosed with age-related macular degeneration - a leading cause of blindness in the over-60s. (Source: the Mail online | Health)
Source: the Mail online | Health - August 14, 2017 Category: Consumer Health News Source Type: news

Ophthotech eye-drug trial fails to meet primary endpoint
Shares in Ophthotech (NSDQ:OPHT) dipped to $2.46 apiece this morning after the company announced that its Phase III wet age-related macular degeneration trial failed to meet its primary endpoint. The New York-based company said that the addition of Fovista (pegpleranib) to Eylea or Avastin, both anti-VEGF therapies, did not significantly improve visual acuity after 12-months compared to Eylea or Avastin alone. Get the full story at our sister site, Drug Delivery Business News. The post Ophthotech eye-drug trial fails to meet primary endpoint appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat ophthotech Source Type: news

Antioxidants No Help for Age-Related Macular Degeneration (CME/CE)
(MedPage Today) -- Little or no benefit with wide range of supplements (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 11, 2017 Category: Geriatrics Source Type: news

Taking vitamin supplements will not prevent a common eye disease
Latest evidence published in the Cochrane Library suggests that taking vitamin supplements, such as vitamin E or beta-carotene, may not prevent the common eye disease age-related macular degeneration (AMD).  See additional resources at the bottom of this pageAge-related macular degeneration (AMD) is a progressive and sight-threatening disease affecting the central area of the retina and affects large numbers of people across the world. Population-based studies suggest that in older people (80 years and older), approximately one in three people have early signs of the disease.There are numerous unanswered questions in ...
Source: Cochrane News and Events - July 31, 2017 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Taking vitamin supplements may slow down the progression of a common eye disease
Latest evidence published in the Cochrane Library suggests that taking a multivitamin supplement that includes vitamin E, carotenoids (beta-carotene or lutein or zeaxanthin), vitamin C, and zinc may slow down the progression of the common eye disease age-related macular degeneration (AMD).See additional resources at the bottom of the pageAge-related macular degeneration (AMD) is a progressive and sight-threatening disease affecting the central area of the retina and affects large numbers of people across the world. Population-based studies suggest that in older people (80 years and older), approximately one in three people...
Source: Cochrane News and Events - July 31, 2017 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Using omega 3 fatty acids to treat Alzheimer's & other diseases?
(Louisiana State University Health Sciences Center) Understanding how dietary essential fatty acids work may lead to effective treatments for diseases and conditions such as stroke, Alzheimer's disease, age-related macular degeneration, Parkinson's disease and other retinal and neurodegenerative diseases. The key is to be able to intervene during the early stages of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2017 Category: International Medicine & Public Health Source Type: news

Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms
Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of age-related macular degeneration (AMD), according to a Danish registry study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

An Eye to Health: Diet and Age-Related Macular Degeneration An Eye to Health: Diet and Age-Related Macular Degeneration
More and more studies are establishing a link between healthy eating and AMD development and progression.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2017 Category: Consumer Health News Tags: Ophthalmology Commentary Source Type: news

Dietary and lifestyle recommendations for patients at risk of macular degeneration
(Dove Medical Press) Age-related macular degeneration (AMD) is a major cause of severe visual impairment in older populations and is characterized by progressive destruction of the retinal pigment epithelial cells and photoreceptors due to low-grade inflammation, ischemia and oxidative stress. Studies show evidence that carotenoids and antioxidants derived either from the diet or from supplements may significantly reduce the risk of visual loss in these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 23, 2017 Category: International Medicine & Public Health Source Type: news

New hope for seniors with vision-robbing disease
The experimental drug for age-related macular degeneration aims to slow the destruction of light-sensing cells in the retina (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 22, 2017 Category: Consumer Health News Source Type: news

Drug shows promise against vision-robbing disease
An experimental drug is showing promise against an eye disease that blinds older adults, according to a US study. Age-related macular degeneration gradually erodes seniors' central vision. (Source: the Mail online | Health)
Source: the Mail online | Health - June 21, 2017 Category: Consumer Health News Source Type: news

Novartis trial results could spell trouble for Regeneron
Head-to-head late-stage clinical trials published on Tuesday showed that a Novartis (NYSE:NVS) drug to treat patients with neovascular age-related macular degeneration doesn’t need to be injected as frequently as a rival drug from competitor Regeneron (NSDQ:REGN). Analysts reportedly said the data gives Novartis’ treatment, RTH258, a competitive edge compared to its rival therapies. Get the full story at our sister site, Drug Delivery Business News. The post Novartis trial results could spell trouble for Regeneron appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Inc. Novartis Regeneron Roche Source Type: news

Aflibercept May Be Effective for Resistant Exudative AMD Aflibercept May Be Effective for Resistant Exudative AMD
Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 14, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

How diet may affect age-related macular degeneration
Switching mice from a high glycemic diet to a low glycemic diet stopped the development of certain signs of age-related macular degeneration. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - June 6, 2017 Category: Consumer Health News Source Type: news

Implant for poor vision helps treat AMD
Age-related macular degeneration is a leading cause of blindness. Bronwen Dunn, 83, a retired administrator from Stoke-on-Trent, had a new operation to improve her sight. (Source: the Mail online | Health)
Source: the Mail online | Health - May 30, 2017 Category: Consumer Health News Source Type: news

Could eating THIS diet prevent blindness as you get older?
AGE-RELATED macular degeneration is the leading cause of blindness in those over 55 in developed countries, but eating low GI foods could stop it. (Source: Daily Express - Health)
Source: Daily Express - Health - May 19, 2017 Category: Consumer Health News Source Type: news